Literature DB >> 6610275

Induction of the morphologic changes of both acute and chronic experimental myasthenia by monoclonal antibody directed against acetylcholine receptor.

C M Gomez, R L Wollmann, D P Richman.   

Abstract

To investigate pathogenic mechanisms in experimental autoimmune myasthenia gravis (EAMG) and myasthenia gravis (MG), we studied the acute and chronic effects in rats of injection of rat monoclonal antibodies ( MCABs ) directed against the acetylcholine receptor (AChR). Animals were severely weak 12 h after a single injection, at which time macrophages were found invading endplate regions of muscle and cholinesterase-stained regions were separted from the underlying muscle fibers. Ultrastructural studies showed findings identical to the acute phase of EAMG: degenerating postsynaptic membranes and invasion and phagocytosis of endplate regions by macrophages. Animals receiving sublethal doses of MCAB recovered clinically by 4-5 days after injection. Recovery was accompanied by a progressive decrease in the number of macrophages associated with endplates and reapposition to the myofibers of the cholinesterase-stained regions. Animals injected once, or repeatedly over several months, remained clinically and electromyographically normal after recovery from the initial episode of weakness, but their endplate ultrastructure was highly simplified with blunted or absent synaptic folds and shallow or absent secondary synaptic clefts. These studies demonstrate that anti-AChR MCABs can induce the changes of both acute and chronic EAMG. There is good correlation between the inflammatory changes and the acute clinical disease but poor correlation between morphological and clinical parameters in the chronic syndrome. The latter observation suggests that severe ultrastructural changes, similar to those seen in chronic EAMG and MG, cannot account, at least in rats, for the clinical and electrophysiologic abnormalities of MG.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610275     DOI: 10.1007/bf00697195

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  48 in total

1.  Neuromuscular transmission after immunization against acetylcholine receptors.

Authors:  D P Green; R Miledi; A Vincent
Journal:  Proc R Soc Lond B Biol Sci       Date:  1975-04-29

2.  Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model.

Authors:  K V Toyka; K L Birnberger; A P Anzil; C Schlegel; U Besinger; A Struppler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-08       Impact factor: 10.154

3.  Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera.

Authors:  S Heinemann; J Merlie; J Lindstrom
Journal:  Nature       Date:  1978-07-06       Impact factor: 49.962

4.  Human myasthenic sera reduce acetylcholine sensitivity of human muscle cells in tissue culture.

Authors:  S Bevan; R W Kullberg; S F Heinemann
Journal:  Nature       Date:  1977-05-19       Impact factor: 49.962

5.  Lymphocyte responsiveness to acetylcholine receptor in rats with experimental autoimmune myasthenia gravis.

Authors:  S A Noguchi; D B Drachman; R N Adams; R L Hirsch
Journal:  Ann Neurol       Date:  1980-07       Impact factor: 10.422

6.  Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation.

Authors:  D B Drachman; C W Angus; R N Adams; J D Michelson; G J Hoffman
Journal:  N Engl J Med       Date:  1978-05-18       Impact factor: 91.245

7.  Acetylcholine receptor antibody in myasthenia gravis: purification and characterization.

Authors:  A K Lefvert; K Bergström
Journal:  Scand J Immunol       Date:  1978       Impact factor: 3.487

8.  End-plate potentials in experimental autoimmune myasthenia gravis in rats.

Authors:  E H Lambert; J M Lindstrom; V A Lennon
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

9.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.

Authors:  I Kao; D B Drachman
Journal:  Science       Date:  1977-04-29       Impact factor: 47.728

10.  Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.

Authors:  A G Engel; J M Lindstrom; E H Lambert; V A Lennon
Journal:  Neurology       Date:  1977-04       Impact factor: 9.910

View more
  5 in total

Review 1.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 2.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 3.  Active oxygen in neuromuscular disorders.

Authors:  A Davison; G Tibbits; Z G Shi; J Moon
Journal:  Mol Cell Biochem       Date:  1988-12       Impact factor: 3.396

4.  Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms.

Authors:  Christopher M Gomez; Ricardo A Maselli; Bhupinder P S Vohra; Manuel Navedo; Joel R Stiles; Pierre Charnet; Kelly Schott; Legier Rojas; John Keesey; Anthony Verity; Robert W Wollmann; Jose Lasalde-Dominicci
Journal:  Ann Neurol       Date:  2002-01       Impact factor: 10.422

5.  Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.

Authors:  David P Richman; Kayoko Nishi; Stuart W Morell; Jolene Mi Chang; Michael J Ferns; Robert L Wollmann; Ricardo A Maselli; Joachim Schnier; Mark A Agius
Journal:  Arch Neurol       Date:  2011-12-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.